RichardJiruiLinMDPhD

Hematologic Oncology, Hospice & Palliative

Assistant Member, Hematopoietic Stem Cell Transplantation, Cellular Therapy, Memorial Sloan Kettering Cancer Center

Overview of Dr. Lin

As a hematopoietic cell transplant/cell therapy clinician, I aim to deliver the best possible care for all patients with advanced hematologic malignancies through my clinical expertise, multidisciplinary team care, and state of art therapeutics and clinical trials. As a clinical investigator, I strive to stay at the academic intersection of hematologic malignancy, transplantation, cellular therapy, and geriatrics/supportive care to improve outcomes for vulnerable older patients, and to identify translational targets in aging pathways for mechanism-based therapy in hematologic malignancies. https://www.mskcc.org/cancer-care/doctors/richard-lin

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(816) 326-2956

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Blood & Bone Marrow Transplant, 2017 - 2019
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2014 - 2017
University of ChicagoResidency, Internal Medicine, 2006 - 2009
Harvard Medical SchoolClass of 2006, MD
University of California San DiegoPhD, Molecular Biology, 1995 - 2001
Nankai UniversityBS, Biochemistry, 1990 - 1994

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2009 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
PA State Medical License 2023 - 2024
IL State Medical License 2006 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Conquer Cancer Foundation of ASCO Merit Award ASCO, 2017
Chief Fellow in Hematology Oncology New York University School of Medicine, 2016
Future Leaders in Hematology Award Celgene Foundation, 2016
Clinical Research Training Institute (CRTI) Award American Society of Hematology, 2016
Merit Award - Palliative Care in Oncology Symposium Conquer Cancer Foundation of ASCO, 2016
Join now to see all

Clinical Trials

Study of CAR-T Therapy in Older Patients Start of enrollment: 2020 Mar 04
Recruiting

Publications & Presentations

PubMed

Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.
Harper Hubbeling, Doris Leithner, Emily A Silverman, Jessica Flynn, Sean Devlin
Clinical Cancer Research. 2024-11-15
1 citations
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.
Gustav Y Cederquist, Javin Schefflein, Sean M Devlin, Gunjan L Shah, Roni Shouval
Blood Advances. 2024-10-08
1 citations
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
Rachel Lorenc, Roni Shouval, Jessica R Flynn, Sean M Devlin, Amethyst Saldia
Transplantation and Cellular Therapy. 2024-10-01

Abstracts/Posters

Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation
Richard J Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...
Richard J Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
Richard J Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell transplantation.
2019 ASCO Annual Meeting - 6/1/2019
A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018